Loading…
Back to Compound Explorer
Lentinan
Clinical trialMechanism of Action
Binds Dectin-1 and complement receptor 3 (CR3) on macrophages, dendritic cells, and NK cells, triggering NF-κB and MAPK signaling cascades. Activates the classical complement pathway (C3 cleavage). Enhances Th1 cytokine production (IL-2, IL-12, IFN-γ), promotes dendritic cell maturation and antigen cross-presentation, and directly enhances NK cell and cytotoxic T-lymphocyte (CTL) activity against tumor cells. Does not have direct cytotoxic activity — mechanism is entirely immune-mediated.
Research Notes
ShiitakeMushroom
Approved as an injectable immunoadjuvant in Japan since 1985 (Ajinomoto Co.) for unresectable/recurrent gastric cancer in combination with tegafur/5-FU chemotherapy. Oba et al. (2009) meta-analysis of 5 RCTs (n=650) demonstrated significant improvement in overall survival (HR 0.80, 95% CI 0.66–0.97) when lentinan was added to chemotherapy in advanced gastric cancer. Hazama et al. (2009) showed median survival improvement from 233 to 406 days in unresectable gastric cancer with lentinan + S-1 chemotherapy. Over 1000 published papers on lentinan since 1969.
Found In 1 Herb
3D Molecular Structure
Beta-1,3/1,6-glucan (high-molecular-weight triple-helix polysaccharide)
Drag to rotate · Click atoms to explore
Lentinan
Beta-1,3/1,6-glucan (high-molecular-weight triple-helix polysaccharide)Complex carbohydrate polymers that modulate immune response
Representative pattern: (C₆H₁₀O₅)ₙ
Atoms
Carbon
Oxygen
Live Research
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare practitioner before using any herbal product.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This content is for educational purposes only and is not a substitute for professional medical advice.